{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:14:59Z","timestamp":1788264899188,"version":"build-2803163510"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Zika virus is a Flavivirus, transmitted via<jats:italic>Aedes<\/jats:italic>mosquitos, that causes a range of symptoms including Zika congenital syndrome. Zika has posed a challenging situation for health, public and economic sectors of affected countries. To quantitate Zika virus neutralizing antibody titers in serum samples, we developed a high throughput plate based Zika virus reporter virus particle (RVP) assay that uses an infective, non-replicating particle encoding Zika virus surface proteins and capsid (CprME) and a reporter gene (<jats:italic>Renilla<\/jats:italic>luciferase). This is the first characterization of a Zika virus RVP assay in 384-well format using a Dengue replicon<jats:italic>Renilla<\/jats:italic>reporter construct. Serially diluted test sera were incubated with RVPs, followed by incubation with Vero cells. RVPs that have not been neutralized by antibodies in the test sera entered the cells and expressed<jats:italic>Renilla<\/jats:italic>luciferase. Quantitative measurements of neutralizing activity were determined using a plate-based assay and commercially available substrate. The principle of limiting the infection to a single round increases the precision of the assay measurements. RVP log<jats:sub>10<\/jats:sub>EC<jats:sub>50<\/jats:sub>titers correlated closely with titers determined using a plaque reduction neutralization test (PRNT) (R<jats:sup>2<\/jats:sup>&gt;95%). The plate-based Zika virus RVP assay also demonstrated high levels of precision, reproducibility and throughput. The assay employs identical reagents for human, rhesus macaque and mouse serum matrices. Spiking studies indicated that the assay performs equally well in different species, producing comparable titers irrespective of the serum species. The assay is conducted in 384-well plates and can be automated to simultaneously achieve high throughput and high reproducibility.<\/jats:p>","DOI":"10.1371\/journal.pone.0250516","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T17:41:25Z","timestamp":1619199685000},"page":"e0250516","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species"],"prefix":"10.1371","volume":"16","author":[{"given":"Kelly","family":"Bohning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sonnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Zahralban-Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Hather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-5594","authenticated-orcid":true,"given":"Hetal K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi J.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"issue":"5","key":"pone.0250516.ref001","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","article-title":"Zika virus. I. Isolations and serological specificity","volume":"46","author":"GW Dick","year":"1952","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"16","key":"pone.0250516.ref002","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1602113","article-title":"Zika Virus","volume":"374","author":"LR Petersen","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0250516.ref003","doi-asserted-by":"crossref","first-page":"e0156376","DOI":"10.1371\/journal.pone.0156376","article-title":"Scoping Review of the Zika Virus Literature","volume":"11","author":"LA Waddell","year":"2016","journal-title":"PLoS One"},{"issue":"31","key":"pone.0250516.ref004","first-page":"858","article-title":"Vital Signs: Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital Zika Virus Infection\u2014U.S. Territories and Freely Associated States, 2018","volume":"67","author":"ME Rice","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"35","key":"pone.0250516.ref005","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1016\/j.vaccine.2011.06.062","article-title":"Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO((R))) induced neutralizing antibody titers","volume":"29","author":"Y Van Gessel","year":"2011","journal-title":"Vaccine"},{"issue":"35","key":"pone.0250516.ref006","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"JG Julander","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"pone.0250516.ref007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"VE Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"issue":"3\u20134","key":"pone.0250516.ref008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF01310983","article-title":"Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report","volume":"93","author":"RJ Phillpotts","year":"1987","journal-title":"Arch Virol"},{"issue":"6","key":"pone.0250516.ref009","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1590\/0074-02760150176","article-title":"A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213\/77 in children nine-23 months old","volume":"110","author":"Collaborative Group for Studies of Yellow Fever V","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"3","key":"pone.0250516.ref010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"B Guy","year":"2010","journal-title":"Vaccine"},{"key":"pone.0250516.ref011","doi-asserted-by":"crossref","first-page":"e2100","DOI":"10.1002\/rmv.2100","article-title":"The role of anti-flavivirus humoral immune response in protection and pathogenesis","author":"AM Hurtado-Monzon","year":"2020","journal-title":"Rev Med Virol"},{"issue":"6309","key":"pone.0250516.ref012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"KA Dowd","year":"2016","journal-title":"Science"},{"issue":"1","key":"pone.0250516.ref013","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"169","author":"JM Richner","year":"2017","journal-title":"Cell"},{"key":"pone.0250516.ref014","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","author":"P Abbink","year":"2016","journal-title":"Science"},{"issue":"1","key":"pone.0250516.ref015","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1038\/s41598-018-34735-7","article-title":"Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice","volume":"8","author":"WR Baldwin","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0250516.ref016","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ebiom.2017.12.010","article-title":"Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge","volume":"27","author":"D Espinosa","year":"2018","journal-title":"EBioMedicine"},{"issue":"7","key":"pone.0250516.ref017","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"SA Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"pone.0250516.ref018","volume-title":"Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses","author":"World Health O","year":"2007"},{"issue":"1","key":"pone.0250516.ref019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tvjl.2012.08.019","article-title":"Review of diagnostic plaque reduction neutralization tests for flavivirus infection","volume":"195","author":"A Maeda","year":"2013","journal-title":"Vet J"},{"issue":"5","key":"pone.0250516.ref020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance","volume":"81","author":"SJ Thomas","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0250516.ref021","unstructured":"Ferguson M, Johnes S, Heath A, World Health Organization. Biologicals U, Standardization WHOECoB. Report of a collaborative study to assess the suitability of candidate reference material to serve as the first WHO reference reagent dengue virus antibody and to standardize the neutralization test for dengue viruses \/ Morag Ferguson\u2026 [et al]. Geneva: World Health Organization; 2005."},{"issue":"25","key":"pone.0250516.ref022","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.vaccine.2014.03.062","article-title":"Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4","volume":"32","author":"GD Gromowski","year":"2014","journal-title":"Vaccine"},{"issue":"16","key":"pone.0250516.ref023","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.77.16.8924-8933.2003","article-title":"Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line","volume":"77","author":"R Gehrke","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"pone.0250516.ref024","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1038\/s41598-020-61103-1","article-title":"Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus","volume":"10","author":"H Garg","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0250516.ref025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2004.10.034","article-title":"Construction and applications of yellow fever virus replicons","volume":"331","author":"CT Jones","year":"2005","journal-title":"Virology"},{"issue":"1","key":"pone.0250516.ref026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.virol.2005.01.021","article-title":"An infectious West Nile virus that expresses a GFP reporter gene","volume":"334","author":"TC Pierson","year":"2005","journal-title":"Virology"},{"issue":"11","key":"pone.0250516.ref027","doi-asserted-by":"crossref","first-page":"e27252","DOI":"10.1371\/journal.pone.0027252","article-title":"Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes","volume":"6","author":"K Mattia","year":"2011","journal-title":"PLoS One"},{"issue":"20","key":"pone.0250516.ref028","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00834-17","article-title":"Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus","volume":"91","author":"H Garg","year":"2017","journal-title":"J Virol"},{"issue":"6","key":"pone.0250516.ref029","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","article-title":"Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype","volume":"16","author":"KA Dowd","year":"2016","journal-title":"Cell Rep"},{"issue":"1","key":"pone.0250516.ref030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2008.08.021","article-title":"Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation","volume":"381","author":"C Ansarah-Sobrinho","year":"2008","journal-title":"Virology"},{"key":"pone.0250516.ref031","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4939-0348-1_6","article-title":"Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection","volume":"1138","author":"S Mukherjee","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"11","key":"pone.0250516.ref032","doi-asserted-by":"crossref","first-page":"e0008730","DOI":"10.1371\/journal.pntd.0008730","article-title":"Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications","volume":"14","author":"JC Whitbeck","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0250516.ref033","unstructured":"Bailey M. JMP software: Custom Design of Experiments Course Notes.: SAS Institute Inc.; 2014 20 March."},{"key":"pone.0250516.ref034","doi-asserted-by":"crossref","unstructured":"Ilya Ravkin VT, Aaron D. Nelson, Michael A. Zarowitz, Matthew Hoopes, Yuli Verhovsky, Gregory Ascue, et al. Multiplexed high-throughput image cytometry using encoded carriers. SPIE. 2004;5322.","DOI":"10.1117\/12.528071"},{"key":"pone.0250516.ref035","unstructured":"Iversen P, Beck B, Chen Y, Dere W, Devanarayan V, Eastwood B, et al. HTS Assay Validation. Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2012."},{"key":"pone.0250516.ref036","unstructured":"ICH Q2 Validation of analytical procedures: text and methodology. In: Teasdale A, Elder D, Nims R, editors. ICH Quality Guidelines: An Implementation Guide2017."},{"key":"pone.0250516.ref037","unstructured":"Anonymous. USP Chapter \u30081033\u3009 Biological Assay Validation. United States Pharmacopeia Convention; 2017."},{"issue":"suppl_10","key":"pone.0250516.ref038","doi-asserted-by":"crossref","first-page":"S928","DOI":"10.1093\/infdis\/jix540","article-title":"Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development","volume":"216","author":"CE Osuna","year":"2017","journal-title":"J Infect Dis"},{"issue":"9","key":"pone.0250516.ref039","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"17","author":"W Dejnirattisai","year":"2016","journal-title":"Nat Immunol"},{"issue":"6301","key":"pone.0250516.ref040","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection","volume":"353","author":"K Stettler","year":"2016","journal-title":"Science"},{"key":"pone.0250516.ref041","doi-asserted-by":"crossref","unstructured":"Han HH DC, Acosta CJ. Safety and immunogenicity of a purified inactivated Zika virus vaccine (PIZV) candidate in healthy adults; a randomized, observer-blind phase 1 clinical trial. Lancet Infectious Disease. 2021; Accepted.","DOI":"10.1016\/S1473-3099(20)30733-7"},{"key":"pone.0250516.ref042","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41541-019-0135-3","article-title":"Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody","volume":"4","author":"G Mattiuzzo","year":"2019","journal-title":"NPJ Vaccines"},{"key":"pone.0250516.ref043","unstructured":"Organization WRotAPAH. PLISA Health Information Platform for the Americas: Cases of Zika virus disease, by country or territory."},{"key":"pone.0250516.ref044","unstructured":"WHO. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. Geneva, Switzerland: WHO; 2016."},{"key":"pone.0250516.ref045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-018-0061-9","article-title":"Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation","volume":"3","author":"ADT Barrett","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"3","key":"pone.0250516.ref046","article-title":"Zika Vaccine Development-Current Progress and Challenges for the Future","volume":"4","author":"JN Maslow","year":"2019","journal-title":"Trop Med Infect Dis"},{"issue":"420","key":"pone.0250516.ref047","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4163","article-title":"Durability and correlates of vaccine protection against Zika virus in rhesus monkeys","volume":"9","author":"P Abbink","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"pone.0250516.ref048","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028902","article-title":"What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection","volume":"10","author":"H Golding","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"suppl_10","key":"pone.0250516.ref049","doi-asserted-by":"crossref","first-page":"S964","DOI":"10.1093\/infdis\/jix433","article-title":"Clinical Development Strategies and Considerations for Zika Vaccine Licensure","volume":"216","author":"MF Gruber","year":"2017","journal-title":"J Infect Dis"},{"key":"pone.0250516.ref050","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1038\/npjvaccines.2016.13","article-title":"First vaccine approval under the FDA Animal Rule","volume":"1","author":"DWC Beasley","year":"2016","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pone.0250516.ref051","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1038\/s41598-020-60415-6","article-title":"Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection","volume":"10","author":"G Young","year":"2020","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0250516.ref052","doi-asserted-by":"crossref","first-page":"e1007766","DOI":"10.1371\/journal.ppat.1007766","article-title":"Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques","volume":"15","author":"ME Breitbach","year":"2019","journal-title":"PLoS Pathog"},{"key":"pone.0250516.ref053","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.meegid.2016.05.004","article-title":"Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas","volume":"43","author":"Q Ye","year":"2016","journal-title":"Infect Genet Evol"},{"issue":"11","key":"pone.0250516.ref054","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41590-018-0227-7","article-title":"Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus","volume":"19","author":"M Renner","year":"2018","journal-title":"Nat Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:02:50Z","timestamp":1698944570000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250516"}},"subtitle":[],"editor":[{"given":"Pierre","family":"Roques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0250516","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}